Home > Quotes > VRTX > Press Releases
VRTX

Vertex Pharmaceuticals Incorporated Press Releases

$78.4
*  
0.08
  negative  
0.1%
Get VRTX Alerts
*Delayed - data as of May 24, 2013 
Exchange: NASDAQ
Industry: Consumer Durables
Community Rating:
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored
Viewing
Filtered By
Ordered By

Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015
05/17/2013 8:30AM - Business Wire

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
05/09/2013 6:07PM - Business Wire

Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C
04/30/2013 4:03PM - Business Wire

Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype
04/24/2013 8:30AM - Business Wire

Netflix Indicating Big Jump Pre-Market on Earnings Surprise - Top Earnings Stocks Ahead of the Bell: Power-One Inc., Goff Corporation, AMR Corporation, Fannie Mae, Vertex Pharmaceuticals
04/23/2013 9:01AM - PR Newswire

ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection
04/23/2013 8:30AM - Business Wire

Cheaper Gas, Airfare, Profits on Way as Commodities Slump Continues? - Top Small Cap Stock Focus Ahead of the Bell:
04/22/2013 8:23AM - PR Newswire

Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
04/18/2013 4:00PM - Business Wire

Unica Founder Yuchun Lee Joins General Catalyst Partners
04/11/2013 8:30AM - Business Wire

Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C
04/05/2013 8:00AM - Business Wire

Vertex to Report First Quarter 2013 Financial Results on Tuesday, April 30
04/01/2013 4:15PM - Business Wire

Pushing Pipelines Forward for Long-Term Success - Research Report on Vertex, Santarus, Arena Pharmaceuticals, Seattle Genetics and Nektar Therapeutics
03/08/2013 8:00AM - PR Newswire

FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval After Just 1 Round of Testing
03/07/2013 8:20AM - Market Wire

VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study
03/04/2013 8:30AM - Business Wire

Vertex Announces Webcasts of its Presentations at Two Investor Conferences
02/27/2013 4:45PM - Business Wire

Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
02/26/2013 4:22PM - Business Wire